LANCL2 - Landos

Unique Pathway

Landos has identified Lanthionine Synthetase C-Like 2 (LANCL2) as a novel therapeutic target for autoimmune diseases, including inflammatory bowel disease (IBD); Crohn’s disease (CD) and ulcerative colitis (UC). Based on extensive preclinical studies, Landos has validated a unique mechanism of action involving LANCL2 that exerts potent anti-inflammatory effects with an outstanding safety profile.


LANCL2: A technology that translates into the human setting

The Landos team has performed human translational studies in blood cells from Crohn’s disease patients. Our results demonstrate that Landos’ preclinical findings translate to humans since BT-11, our LANCL2-binding small molecule for IBD, increases anti-inflammatory molecules, such as IL-10 and FOXP3, and decreased pro-inflammatory markers, such as MCP1, TNFα, and IFNγ in human immune cells.

LANCL2 Charts

Patent Table